

High expression of *MAP7* predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia

**Lin Fu<sup>1,2,3\*</sup>, Huaping Fu<sup>4,\*</sup>, Lei Zhou<sup>5,\*</sup>, Keman Xu<sup>6</sup>, Yifan Pang<sup>7</sup>, Kai Hu<sup>1</sup>, Jing Wang<sup>1</sup>, Lei Tian<sup>1</sup>, Yuanyuan Liu<sup>1</sup>, Jijun Wang<sup>1</sup>, Hongmei Jing<sup>1</sup>, Wenrong Huang<sup>5</sup>, Xiaoyan Ke<sup>1</sup>, Jinlong Shi<sup>2</sup>**

<sup>1</sup>Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China

<sup>2</sup>Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, 100853, China

<sup>3</sup>Blood Diseases Institute, Xuzhou Medical University, Xuzhou, 221002, China

<sup>4</sup>Department of nuclear medicine, Chinese PLA General Hospital, Beijing, 100853, China

<sup>5</sup>Department of Hematology, Chinese PLA General Hospital, Beijing, 100853, China

<sup>6</sup>College of medical laboratory science and technology, Harbin Medical University, Daqing, 163319, China

<sup>7</sup>Department of Medicine, William Beaumont Hospital, Royal Oak, MI, 48073, USA

\*These authors contributed equally to this work.

Correspondence and requests for materials should be addressed to:


J.L.S. (E-mail: [jinlong\\_301@163.com](mailto:jinlong_301@163.com)) or X.Y.K. (E-mail: [xiaoyank@yahoo.com](mailto:xiaoyank@yahoo.com)) or W.R.H (E-mail: [huangwr301@163.com](mailto:huangwr301@163.com))

**Table S1.** Characteristics of the 88 CN-AML patients in the second independent cohort segregated based on *MAP7* expression level


<b>Variable</b>	<b><i>MAP7</i><sup>high</sup>, n=44</b>	<b><i>MAP7</i><sup>low</sup>, n=44</b>	<b><i>P</i></b>
Median age. y (range)	46 (19-59)	47(17-59)	0.67
FAB subtype, no (%)			
M0	0 (0.0)	3 (6.8)	0.24
M1	13 (29.5)	7 (15.9)	0.21
M2	11 (25.0)	9 (20.5)	0.8
M4	16 (36.4)	12 (27.2)	0.49
M5	3 (6.8)	10 (22.7)	0.033
M6	1 (2.3)	3 (6.8)	0.62
High <i>ERG</i> , no (%)	31 (70.5)	13 (29.5)	<0.001
High <i>BAALC</i> , no (%)	21 (47.8)	23 (52.3)	0.83
High <i>LEF1</i> , no (%)	14 (31.8)	30 (68.2)	0.001
High <i>WT1</i> , no (%)	34 (77.3)	10 (22.7)	<0.001
High <i>DNMT3B</i> , no (%)	33 (75.0)	11 (25.0)	<0.001
High <i>DNMT3A</i> , no (%)	28 (63.6)	16 (36.4)	0.02
High <i>MAPKBP1</i> , no (%)	31 (70.5)	13 (29.5)	<0.001
High <i>ITPR2</i> , no (%)	37 (84.1)	7 (15.9)	<0.001
High <i>ATP1B1</i> , no (%)	33 (75.0)	11 (25.0)	<0.001

**FAB**, French-American-British classification.


High *ERG*, *BAALC*, *LEF1*, *WT1*, *DNMT3B*, *DNMT3A*, *MAPKBP1*, *ITPR2* and *ATP1B1* expression were defined as an expression level above the median of all samples, respectively.






Supplementary Figure 1. A schematic diagram of the systematic strategies for uncovering the prognostic significance of *MAP7* in CN-AML patients.



Supplementary Figure 2. MAP7 levels in various different subgroups of AML patients.



Supplementary Figure 3. OS of CN-AML patients in the second independent



Supplementary Figure 4. Median value of *MAP7* expression as the cut-off. (A) *MAP7* expression is normally distributed. (B) OS and (C) EFS AML patients were subdivided into four quartiles based on the quartile of *MAP7* expression.